The Zhitong Finance App learned that Huatai Securities covered Deshai-B (02526.HK) for the first time and gave it a “buy” rating, with a target price of HK$296.13. The bank is optimistic that in the context of the accelerated release of demand for intelligent medical imaging, the company will continue to improve the development and commercialization efficiency of specialist models with cross-modal model capabilities, hospital cooperation networks, and clinical data accumulation, and expand revenue boundaries through model training, software licensing, and sequential segmentation, replicate existing capabilities to more scenarios, and promote the expansion of total revenue and recurring revenue scale for model services.

The Zhitong Finance App learned that Huatai Securities covered Deshai-B (02526.HK) for the first time and gave it a “buy” rating, with a target price of HK$296.13. The bank is optimistic that in the context of the accelerated release of demand for intelligent medical imaging, the company will continue to improve the development and commercialization efficiency of specialist models with cross-modal model capabilities, hospital cooperation networks, and clinical data accumulation, and expand revenue boundaries through model training, software licensing, and sequential segmentation, replicate existing capabilities to more scenarios, and promote the expansion of total revenue and recurring revenue scale for model services.